+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ingrezza"

From
Ingrezza Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Ingrezza Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
Tourette Syndrome Treatment Market - Product Thumbnail Image

Tourette Syndrome Treatment Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
Tardive Dyskinesia Treatment Market 2024-2028 - Product Thumbnail Image

Tardive Dyskinesia Treatment Market 2024-2028

  • Report
  • November 2023
  • 147 Pages
  • Global
From
  • 12 Results (Page 1 of 1)
Loading Indicator

Ingrezza is a Central Nervous System (CNS) drug used to treat adults with tardive dyskinesia, a neurological disorder characterized by involuntary, repetitive movements. It is the first and only FDA-approved treatment for this condition. Ingrezza works by blocking the dopamine receptor, which is thought to be responsible for the abnormal movements associated with tardive dyskinesia. The Ingrezza market is composed of pharmaceutical companies that manufacture and distribute the drug. These companies are responsible for researching, developing, and marketing the drug to healthcare providers and patients. They also provide support services such as patient education and reimbursement assistance. Some companies in the Ingrezza market include Neurocrine Biosciences, Inc., Teva Pharmaceuticals, and Mylan N.V. Show Less Read more